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Outpatient parenteral antimicrobial therapy (OPAT) is a safe, effective,
and convenient treatment strategy for patients receiving intravenous antimicrobials
in the outpatient setting; however, data are limited describing the use and safety of
liposomal amphotericin B (L-AMB). Records of patients receiving L-AMB OPAT
between 1/1/2015 and 7/31/2018 were retrospectively reviewed. The primary objective was to describe the OPAT patient population discharged on L-AMB and evaluate
factors associated with readmission and adverse events (AEs). Analysis was performed to evaluate for predictors of worse outcomes. Forty-two patients (67% male,
median age 50 years) were identiﬁed, most of whom were treated for histoplasmosis.
The most common doses of L-AMB were 3 mg/kg (n = 16, 38%) or 5 mg/kg (n = 14,
33%) based on actual body weight. Twenty-six (62%) patients completed their anticipated course of L-AMB. Twenty-two (52%) patients were readmitted within 30 days
of discharge; median time to readmission was 11 days (interquartile range [IQR] 5 to
18). While hypokalemia and acute kidney injury (AKI) were common, occurring in 26
(62%) and 20 (48%) patients, respectively, only 5 (12%) were readmitted to the hospital due to L-AMB-associated AEs. Ninety percent of patients achieved at least partial renal recovery within 30 days after L-AMB discontinuation. Factors signiﬁcantly
associated with AKI include higher L-AMB dose, lower serum potassium levels after
therapy initiation, and receipt of potassium supplementation at discharge. L-AMB is
associated with signiﬁcant AEs; however, these results suggest that treatment is feasible in the outpatient setting with close monitoring, as the majority of AEs were
managed effectively in an outpatient without long-term sequelae.
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O

utpatient parenteral antimicrobial therapy (OPAT) allows outpatient continuation
of intravenous (IV) antimicrobials, reducing hospital length of stay and health
care-associated costs while increasing patient satisfaction (1–3). However, OPAT is not
without risks and complications. Decreased provider supervision increases risk of undetected and untreated adverse events (AEs). Additionally, implementation of OPAT programs assisting in transitions of care and monitoring is low (4–6).
Available OPAT data primarily report antibiotic outcomes, but information is lacking
regarding amphotericin B (AMB) for invasive fungal infections (IFIs) treatment. Patients
with IFIs are often complex with signiﬁcant comorbidities, like immune deﬁciency,
malignancy, and transplant recipients, and frequently require prolonged durations of
therapy (7–9). AMB remains the broadest spectrum systemic antifungal since its 1950s
introduction and is often the most effective agent for many IFIs (9, 10). However, therapy is frequently limited by toxicity, including infusion reactions, electrolyte aberrations, and nephrotoxicity (10). Lipid formulations, now mainstays of therapy, are associated with less toxicity than that of conventional deoxycholate (11). Liposomal
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Characteristic
Age
Sex (Male)

Median (IQR) or
n (%) (N = 42)
50 (37–62)
28 (67)

Comorbidities
Malignancy
Solid tumor malignancy
Hematologic malignancy
Chemotherapy
Immunosuppressive medications (steroids, biologics, DMARDs)
Diabetes mellitus
Stem cell transplant recipients
Solid organ transplant recipients
Human immunodeﬁciency virus

19 (45)
3 (7)
16 (28)
15 (36)
9 (21)
6 (14)
6 (14)
1 (2)
3 (7)

Site of infection
Disseminated
Pulmonary
Central nervous system
Gastro-intestinal/abdominal organs
Sinusitis
Adrenal
Endocarditis
Candidemia
Osteomyelitis
Urinary tract

19 (45)
11 (26)
6 (14)
4 (10)
3 (7)
3 (7)
2 (5)
2 (5)
1 (2)
1 (2)

Type of fungal infection
Histoplasmosis
Aspergillus (including possible Aspergillus pneumonia)
Cryptococcus
Candida
Blastomyces
Mucorales
Others: Fusarium, Irpex lacteus, Rhodoturula, Ustilago, and possible
dematiaceous fungus

13 (31)
7 (17)
6 (14)
5 (12)
3 (7)
2 (5)
5 (12) (one patient [2%]
in each category)

aIQR,

interquartile range; DMARDs, disease modifying anti-rheumatoid drugs; HIV, human immunodeﬁciency
virus.

amphotericin B (L-AMB) is the most widely used lipid formulation, but toxicity persists
despite routine intensive monitoring, adding to the complexity of managing patients
in less-supervised settings (11–16).
In the literature, AMB OPAT use is infrequent, ranging from 1 to 2% (2, 4, 12, 17–22).
Additionally, these studies include various AMB products for both prophylactic and
therapeutic indications. This study seeks to deﬁne patient populations receiving L-AMB
OPAT for IFI treatment and determine rates and factors associated with readmission
and AEs.
RESULTS
Forty-two patients received L-AMB OPAT between 01/01/2015 and 07/31/2018.
Median age was 50 years (IQR 37 to 62) and 28 (67%) were male. The most common
comorbidities were malignancy, receipt of immunosuppressive agents, diabetes mellitus, and receipt of stem cell transplant, in 19 (45%), 9 (21%), 6 (14%), and 6 (14%)
patients, respectively. Histoplasmosis was the most common indication (13 [31%]), followed by aspergillosis (7 [26%]) and cryptococcosis (6 [14%]) (Table 1). Thirty-nine
patients (93%) initiated therapy during hospital admission, with median length of stay
of 9 days (IQR 5 to 22) (Table 2), while three (7%) started as outpatients. Most, 35
(83%), were managed with home infusion pharmacy and nursing services, four at
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TABLE 1 Baseline and clinical characteristicsa
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TABLE 2 Therapy characteristics and outcomesa
Therapy characteristic or outcome
Liposomal amphotericin B dose, mg/kg

Median (IQR) or
n (%) (N = 42)
4 (3–5)

Liposomal amphotericin B dose distribution
,3 mg/kg
3 mg/kg
4 mg/kg
5 mg/kg
.5 mg/kg

3 (7)
16 (38)
7 (17)
14 (33)
2 (5)

Index hospitalization length of stay (39 patients), daysb
Hypokalemia during index admissionb
Signiﬁcant hypokalemia during index admissionb
Nadir potassium during index admissionb
Serum creatinine at discharge, mg/dl
Serum potassium value at discharge, mmol/liter
Serum magnesium value at discharge, mg/dl
Concomitant nephrotoxic agent (vancomycin, tacrolimus)

9 (5–22)
25 (64)
13 (33)
3.1 (2.8–3.5)
0.9 (0.7–1.1)
3.8 (3.5–3.9)
1.9 (1.7–2)
8 (19)

OPAT location
Home
SNF/LTAC
Infusion center

35 (83)
4 (10)
2 (7)

Readmission
30-day hospital readmission
Time to readmission, days
Reason for 30-day hospital readmission (N = 22 [52%])
Adverse drug reaction
Acute kidney injury
Hypokalemia
Worsening of infection
Other reasons, e.g., graft versus host disease, stem cell transplant,
Clostridioides difﬁcile infection, bacterial sepsis

28 (14–42)
26 (14–37)
14 (10–26)
23 (55)
18 (14–30)
2 (1–2.5)
20 (48)
1.29 (1–1.59)
8.5 (5–14)
21 (50)
26 (62)
16 (38)
22 (52)
3.1 (2.8–3.7)
7 (4–9)
12 (29)
1.6 (1.5–1.9)
22 (52)
11 (5–18)
5 (12)
3
2
3 (7)
14 (33)

aIQR,

interquartile range; L-AMB, liposomal amphotericin B; ID, infectious diseases; OPAT, outpatient parenteral
antimicrobial therapy; SNF, skilled nursing facility; LTAC, long-term acute care facility.
bAnalysis included only those who were started during a hospitalization and did not include three patients
started as an outpatient.
cWhen scored on the Naranjo scale, all cases met at least probable criteria due to temporal sequence, recognized
AEs, and improvement upon withdrawal (32).
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OPAT clinical course
Duration
Planned length, days
Actual total duration, including inpatient and outpatient (40 patients), days
Outpatient duration of therapy, days
Completion of L-AMB course fully as an outpatient
Median duration of therapy for those completing full course as an
outpatient, days
Monitoring laboratory frequency, times per wk
Renal toxicityc
Acute kidney injury
Maximum serum creatinine after discharge, mg/dl
Time to acute kidney injury, days
Patients received concomitant intravenous hydration with L-AMB
Electrolyte managementc
Hypokalemia (K , 3.5 mmol/liter) after discharge
Severe hypokalemia (K , 3.0 mmol/liter) after discharge
Potassium supplement prescribed at discharge
Nadir potassium after discharge, mmol/liter
Time to nadir hypokalemia, days
Magnesium supplement prescribed at discharge
Nadir magnesium after discharge, meq/liter
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postacute care facilities (PACFs), and two at infusion centers (Table 2). Labs were drawn
a median of twice weekly (IQR 1 to 2.5). The most common L-AMB daily doses were 3
and 5 mg/kg, 16 (38%) and 14 (33%), respectively. Median total duration of therapy
(inpatient and outpatient) was 26 days (IQR 14 to 37), and median OPAT duration was
14 days (IQR 10 to 26), resulting in 1,042 total OPAT days.
Twenty-two patients (52%) were readmitted within 30 days, occurring at a median
of 11 days (IQR 5 to 18) (Table 2). Five patients (12%) were readmitted due to L-AMBassociated AEs (two for hypokalemia [serum potassium {K} 1.9 and 2.4 mmol/liter] and
three for AKI) and three (7%) were readmitted due to worsening of IFI. Remaining readmissions, 14 (33%), were due to factors unrelated to L-AMB or IFI. No factors were signiﬁcantly associated with readmission; however, readmissions were numerically higher
in patients with malignancy (13/22 [59%] versus 6/20 [30%], odds ratio [OR] 3.37, 95%
conﬁdence interval [CI] 0.94 to 12.11).
Mortality occurred in two patients, both of whom developed AKI during therapy,
due to progression of fungal disease (disseminated mold infection and resistant
Candida glabrata candidemia).
Twenty-six (62%) patients completed their anticipated L-AMB duration (Fig. 1). This
included patients who were readmitted but for whom L-AMB continued as planned.
Twenty-three (55%) completed L-AMB as outpatients, with a median duration of
18 days (IQR 14 to 30 days) (Table 2). L-AMB was held in nine patients (21%) for AE
management but was resumed and courses were completed successfully. Of those
with early L-AMB discontinuation, 88% switched to an azole antifungal. Four patients
experienced infusion reactions, two with rigors or chills and one each with fever and
anaphylaxis.
Upon L-AMB OPAT initiation, median serum creatinine (SCr) was 0.9 mg/dl (IQR
0.7 to 1.1); however, 20 patients (48%) developed AKI at a median of 8.5 days (IQR 5
to 14). This occurred despite 50% (n = 21) receiving concurrent IV hydration. Factors
associated with AKI (Table 3) included lower inpatient serum potassium after L-AMB
initiation (3 versus 3.3 mmol/liter, P = 0.04), discharge prescription of potassium supplementation (70% versus 36%, OR 4.1, 95% CI 1.1 to 14.9), and higher L-AMB dose
(4.6 versus 3.2 mg/kg, P = 0.05). Intravenous hydration was not associated with lower
AKI risk (45% versus 55%, OR 0.7, CI 0.2 to 2.3). No patients with AKI developed hyperkalemia, and median outpatient maximum potassium was 4.3 mmol/liter (IQR 2.9
to 5).
Of those who developed AKI, ﬁve (25%) achieved full renal recovery within
30 days after discontinuation, while all surviving patients, 18 (90%), experienced at
least partial recovery. At 1 year postdiscontinuation, 13 (65%) experienced full renal
recovery at a median of 54 days (range 30 to 309). AKI management was
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FIG 1 Outcomes of liposomal amphotericin B OPAT therapy.
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TABLE 3 Factors associated with acute kidney injury (bivariate analysis)a

Variable
Age, yrs
Sex, male
Diabetes mellitus
L-AMB dose, mg/kg
Index hospitalization length of stay, days
Frequency of laboratory monitoring, times per wk
Duration of therapy of L-AMB therapy, days
Patient received concomitant IV hydration
Concomitant nephrotoxic agent
Serum creatinine at hospital discharge, mg/dl
Peak serum creatinine, mg/dl
Serum potassium at hospital discharge, mmol/liter
Potassium supplementation prescribed at discharge
Nadir potassium after discharge, mmol/liter
Hypokalemia (K , 3.5 mmol/liter) during index hospitalization
Signiﬁcant hypokalemia (K , 3.0 mmol/liter) during index
hospitalization
Nadir potassium level during index hospitalization
Serum magnesium at hospital discharge, mg/dl
Magnesium supplementation prescribed at discharge
Nadir magnesium after discharge, mg/dl

No acute kidney injury
median (IQR) or n (%)
(N = 22 [52%])
48 (37–59)
17 (77)
2 (9)
3.2 (3–4.4)
10 (5–24)
2 (1–2)
26 (14–43)
12 (55)
2 (9)
0.87 (0.7–1)
1 (0.9–1.2)
3.8 (3.5–3.9)
8 (36)
3.1 (2.7–3.6)
10 (48)
4 (19)

P value
0.80
0.19
0.40
0.05
0.65
0.34
0.91
0.54
0.12
0.45
NA
.0.99
0.03
0.53
0.10
0.16

3 (2.7–3.2)
1.8 (1.6–1.9)
7 (35)
1.6 (1.3–1.7)

3.3 (3.1–3.8)
1.9 (1.8–2)
5 (23)
1.8 (1.6–2)

0.04
0.08
0.50
0.06

Odds
ratio

95%
conﬁdence
interval

0.4
2.5

0.1–1.4
0.4–15.4

1.3

0.6–2.5

0.7
4.3

0.2–2.3
0.8–24.4

NA
4.1

1.1–14.9

3.9
3.4

0.9–15.7
0.8–14.2

1.8

0.5–7.1

interquartile range; ID, infectious diseases; IV, intravenous; L-AMB, liposomal amphotericin B; NA, not applicable.

determined based on clinical judgment, resulting in 7 (35%) conversions to azole
antifungals; however, 13 continued L-AMB. Seven (35%) were monitored and did
not require therapy adjustment, 3 (15%) adjusted frequency to 48 h, and 1 (5%)
adjusted frequency to thrice weekly. No patient required hemodialysis due to
L-AMB nephrotoxicity.
Potassium was within normal limits for over 75% of patients upon initiation of
L-AMB OPAT; however, despite supplementation in 22 (52%), 26 (62%) developed hypokalemia, median nadir of 3.1 mmol/liter (IQR 2.8 to 3.7). Sixteen (38%) developed
severe hypokalemia, associated with age (40 versus 59 years, P = 0.05), L-AMB durations (30 versus 19.5 days, P = 0.02), and nadir magnesium (1.5 versus 1.7 meq/liter,
P = 0.04).
DISCUSSION
To date, few reports detail L-AMB OPAT experiences (12, 21–23). This is the largest
description of adult L-AMB OPAT patients, most of whom received daily infusions. We
sought to determine rates and reasons for readmission and AEs to better understand
this patient population and provide a description of L-AMB OPAT.
As expected with this complex population, readmission rates were high, occurring
in 22 (52%) patients. However, most readmissions were unrelated to L-AMB, 14
(33%), with only 5 (12%) due to L-AMB-associated AEs (3 AKI and 2 hypokalemia).
No factors were signiﬁcantly associated with readmission; however, patients with
malignancy were more frequently readmitted. L-AMB-associated readmission rates
are similar to those from a previous study of outpatient amphotericin (12%); however, nonlipid AMB formulations were included in that study (12). In a study reporting
thrice-weekly L-AMB OPAT, readmissions occurred in 22%, but only one (6%) readmission was attributed to L-AMB AKI (21). L-AMB-associated readmissions occurred in
17% (2/12) of patients in a study of antifungal OPAT that also utilized thrice-weekly
administration (22).
High AE rates (20 to 72%) associated with lipid formulations are most notably due
to AKI, varying between 9 and 25%, and electrolyte abnormalities (12–14). Compared
to those in AMB deoxycholate, incidences of nephrotoxicity and infusion reactions are
June 2021 Volume 65 Issue 6 e01876-20
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aIQR,

Acute kidney injury
median (IQR) or n (%)
(N = 20 [48%])
56 (37–63)
11 (55)
4 (20)
4.6 (3.3–5.1)
9 (7–18)
2 (1–3)
27.5 (14.5–35)
9 (45)
6 (30)
0.9 (0.7–1.2)
1.6 (1.4–1.8)
3.8 (3.5–3.9)
14 (70)
3.2 (2.9–3.8)
14 (78)
8 (44)
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lower with L-AMB and other lipid formulations (14, 24). Previous data suggest that
there may not be a strong association with AEs and L-AMB dose; however, we noted
an association with increased L-AMB dose and AKI (24–26). Most data regarding LAMB-associated AEs describe inpatients, but in one study evaluating outpatient AMB,
nephrotoxicity occurred in 50% of adults (12).
Conﬂicting nephrotoxicity deﬁnitions are present in AMB literature. These ranged
from our deﬁnition, 0.5 mg/dl or 50% increase from baseline SCr, to $1 mg/dl increase
or doubling of baseline SCr (11, 12, 14, 21, 24). As such, rates range from 10 to 56%
depending on deﬁnitions used (11, 12, 14, 21, 24). A more conservative deﬁnition was
used in this study, reﬂecting clinical practice of our OPAT program.
Sodium loading has reduced nephrotoxicity in hospitalized patients receiving AMB
deoxycholate (12, 27, 28). Half of our patients received sodium loading via IV hydration
with normal saline pre- and postinfusion upon OPAT initiation; however, this rose to
31 (74%) after intervention by the OPAT team. This is consistent with sodium loading
practices reported in a survey of inpatient clinical pharmacists regarding prophylactic
strategies to prevent AMB lipid formulation AEs, in which 68% reported routine use of
IV ﬂuid boluses (29), and similar to a previous report of community-based AMB, in
which 50% received sodium loading (12). Unlike AMB deoxycholate, a trend toward
lower nephrotoxicity was not seen in patients who received sodium loading, and it is
unclear whether this beneﬁt exists for L-AMB, as studies have not assessed effect on
lipid formulations. Conversely, excessive ﬂuid loading may play a role in exacerbating
potassium wasting in the setting of magnesium deﬁciency (30).
Previous studies reporting AMB OPAT found that high rates of nephrotoxicity occurred
in older patients, those who had received a solid organ transplant, and those who were
receiving concomitant cyclosporine (12). We observed an association with lower inpatient
potassium levels and potassium supplementation on discharge. It is possible that hypokalemia is an early sign of L-AMB-induced nephrotoxicity. Magnesium deﬁciency may exacerbate hypokalemia and render it refractory to treatment by potassium replacement (30). As
such, patients with magnesium deﬁciency may be unable to replete potassium stores with
potassium supplementation alone.
While AKI occurred frequently, no patient required hemodialysis. Patients achieved
full renal recovery after discontinuation up to a rate of 65%, with 25% recovering
within 30 days, similar to the results in prior reports (31). However, it should be noted
for those with incomplete renal recovery that there may be implications affecting
future therapy choices for underlying disease, emphasizing that L-AMB is not benign.
While two patients died and experienced worsening renal function while on L-AMB,
mortality was attributed to worsening infection. Inpatient management for patients at
high risk for complications and those indicated for shorter courses may provide an opportunity for closer monitoring, allowing for earlier AE detection.
AEs were common, requiring close supervision by the OPAT team, which allowed
for attentive and frequent laboratory monitoring, timely electrolyte replacement, and
therapy adjustments. Over the last decade, OPAT team utilization has expanded, allowing for more comprehensive outpatient management. In a 2018 infectious diseases
(ID) physician survey, 36% reported OPAT program utilization, up from 26% in 2012 (5,
6). Despite increased OPAT programs, signiﬁcant barriers to care still exist.
IDSA’s 2018 Clinical Practice Guidelines for the Management of OPAT recommends
at least twice-weekly monitoring of potassium and SCr and weekly liver function tests
(LFT) and complete blood counts (CBC) for L-AMB (1). In a survey of OPAT practices
among adult ID physicians, 415/450 responded regarding L-AMB monitoring frequency; 47% reported twice-weekly monitoring, followed by once- (24%) and thriceweekly (22%) monitoring (5). The Washington University School of Medicine (WUSM)
ID OPAT team provides recommendations for thrice-weekly basic metabolic panels
and once-weekly CBC and LFTs, guiding providers ordering laboratory studies on discharge. Despite this recommendation, we found that patients most often received
twice-weekly studies (IQR 1 to 2.5). Patients with severe hypokalemia received more
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frequent monitoring, likely due to increased monitoring after supplementation and
trending potassium losses. High-frequency monitoring may not be feasible for all situations, but we agree with at least twice-weekly laboratory monitoring.
Barriers to OPAT transitions of care include appropriate discharge ordering of laboratory studies, access to outpatient laboratory data, and communication between
OPAT teams and patients or PACF (6). First-hand experience in management of this
population reveals that while barriers may be overcome by a dedicated and efﬁcient
OPAT team, signiﬁcant manpower is necessary to address these issues. Additionally,
clear and efﬁcient communication among team members and patients is paramount,
due to frequent therapy adjustments to mitigate AEs. Appropriate patient selection, of
stable patients in whom prolonged hospitalization may be detrimental, also aids in
successful OPAT courses. Developing action plans in anticipation of AEs, such as
thresholds for therapy adjustments or electrolyte replacement, allows for quick action
from the OPAT team and decreases time to intervention. In review of these data, reduction in L-AMB frequency may be an effective management strategy given L-AMB’s long
half-life, as seen in a few recent reports (21–23).
Limitations are those inherent to retrospective studies, as data were collected from
chart review and limited to provider documentation. While numbers were small, given
the rarity of L-AMB OPAT, it is a relatively large study. The small sample size limits abilities to assess readmission and AE contributing factors, though some associations may
be helpful when caring for this challenging patient population.
Strength of this study lies in examination of L-AMB OPAT in the current era of more
prevalent OPAT programs. Few studies have evaluated outpatient AMB and included
prolonged study periods (5 to 10 years) and multiple AMB formulations. This study is
unique, as prophylactic dosing was excluded. Patients received higher and more frequent
dosing than those on prophylaxis, allowing for inclusion of a population more likely to experience AEs. In addition, all patients in this study received L-AMB, while previous studies
report on mixed use of AMB deoxycholate and lipid formulations (12, 18–20). This study
provided real-life experience with L-AMB OPAT, reporting clinically relevant outcomes,
including readmission, signiﬁcant hypokalemia, AKI, and associated factors.
Treatment with L-AMB OPAT is feasible but not without risks. With close monitoring
and early intervention, OPAT teams can effectively manage a majority of L-AMB-associated AEs, without readmission or long-term sequelae. As OPAT programs continue to
expand, additional work is needed to mitigate barriers to effective OPAT care, such as
laboratory data access, correct discharge laboratory monitoring orders, and detecting
transitions of care errors in these high-risk patients.
MATERIALS AND METHODS
This retrospective cohort consists of patients of $18 years who were managed by Washington
University School of Medicine (WUSM) in St. Louis, Division of Infectious Diseases (ID) OPAT team
receiving outpatient L-AMB from 01/01/2015 to 07/31/2018. Only L-AMB treatments prescribed for
therapeutic purposes were included, excluding lower prophylactic doses. The WUSM ID OPAT team,
consisting of an ID physician and pharmacist, midlevel providers, and nurses, coordinates transitions of
care, monitors laboratory results (at minimum once weekly), and cares for .1,500 patients annually.
Patients were identiﬁed utilizing the OPAT database maintained by clinic nurses and ID pharmacist.
Patients are referred to the OPAT team via ID consult during hospitalization at Barnes-Jewish Hospital,
a 1,368-bed academic medical center, or outpatient referral. Patients received L-AMB at home with
home infusion pharmacy and nursing, at postacute care facilities (PACF), or at outpatient infusion
centers.
Data points were abstracted from the electronic medical record utilizing a standardized data collection form by two abstractors and included patient demographics, comorbidities, concomitant medications, laboratory data, IFI indication, L-AMB dosage, electrolyte supplementation, IV hydration, 30-day
hospital readmission data, and reported AEs. Discrepancies were resolved by discussion with study
investigators (Y. J. Burnett, Y. Hamad). Data were managed using REDCap (Research Electronic Data
Capture), a secure, web-based application hosted by Washington University School of Medicine Institute
for Informatics, Informatics Core Services. Deidentiﬁed data were downloaded and stored via a secure
server for statistical analysis. The study was approved by the Human Research Protection Ofﬁce at
Washington University in St. Louis.
Study deﬁnitions include the following. Acute kidney injury (AKI): 0.5 mg/dl or 50% increase from
baseline serum creatinine (SCr). Full renal recovery: return to 50% of baseline SCr at 30 days and 1 year
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after L-AMB discontinuation. Partial renal recovery: decrease by one stage of chronic kidney disease.
Hypokalemia: K , 3.5 mmol/liter. Severe hypokalemia: K , 3.0 mmol/liter. Hypomagnesemia: Mg , 1.5
meq/liter. Infusion reactions: chills, fever, nausea, vomiting, dyspnea, chest pain, hypotension, and muscle spasm during or immediately following L-AMB infusion. AEs were classiﬁed in accordance with the
Naranjo adverse drug reaction probability scale (32). Indication and planned duration of therapy were
obtained from the ID provider note. For indeﬁnite or long-term planned durations, 90 days was used as
an estimate of how long patients may tolerate therapy.
Descriptive statistics analyzed baseline characteristics, care-related measures, and readmissions. Chisquare test analyzed categorical values, while Wilcoxon rank sum was used for continuous values. Odds
ratios and 95% conﬁdence intervals were calculated for categorical variables. Missing values were eliminated from analysis.
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